GlaxoSmithKline files for European approval of diabetes drug albiglutide
LONDON (Reuters) - Britain's biggest drugmaker GlaxoSmithKline said on Thursday it had filed for European approval of its new once-weekly diabetes drug albiglutide, as tries to gain a foothold in a crowded market.
Albiglutide, used to treat type 2 diabetes, belongs to the same class of injectable GLP-1 medicines as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca's Amylin unit.
The drug has not yet been approved anywhere in the world, GSK said.
As a latecomer to the GLP-1 market, however, analysts believe albiglutide may struggle to generate major sales.
GSK made a similar submission in the United States in January for albiglutide, one of a number of new drugs the company hopes will revive its product portfolio.
(Reporting by Alice Baghdjian; Editing by Paul Sandle)
- U.S. air strikes on Syria would face formidable obstacles
- Samsung unveils smartwatch that can make calls
- Russian-backed separatists enter southeast Ukraine town
- FBI, Secret Service investigate reports of cyber attacks on U.S. banks
- Breakthrough hopes dented as Ukraine accuses Russia of new incursion |